Opendata, web and dolomites

CerviVax

New Generation Therapeutic vaccine for the Treatment of HPV infections and Cervical Dysplasia

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CerviVax project word cloud

Explore the words cloud of the CerviVax project. It provides you a very rough idea of what is the project "CerviVax" about.

   proprietary    papilloma    preliminary    virus    hpv    innovative    position    adyuvant    dropbox    ch    diseases    phase    licensed    empty    treat    proof    of    therapies    technological    ibdv    bursal    immune    validated    lesions    direct    vlpbio    antigens    efficacy    clinical    pharma    license    diligence    https    prevent    model    induce    company    exist    detected    business    commercial    mov    solutionsto    larger    p2s06bqm9toai3n    vlp    absence    16    surgery    caused    unmet    chimeric    animal    excellent    infection    patented    cervivax    platform    dl    submitting    overpassing    vaccine    treatment    pathologies    viral    markets    potentiate    chemotherapy    com    biotech    world    cellular    cover    companies    solutions    cervical    proofs    agreements    vaccines    immunotherapeutic    prophylactic    pharmaceutical    therapeutic    dysplasia    human    biotechnological    humoral    combined    infections    vivo    particles    incorporating    disease    fight    status    immunogenic    responsible    infectious   

Project "CerviVax" data sheet

The following table provides information about the project.

Coordinator
VLP THE VACCINES COMPANY 

Organization address
address: CALLE VELAZQUEZ NUMERO 4-5 A
city: SALAMANCA
postcode: 37005
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.vlpbio.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-09-01   to  2016-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VLP THE VACCINES COMPANY ES (SALAMANCA) coordinator 50˙000.00

Map

 Project objective

VLPbio (www.vlpbio.com) is a biotechnological company applying immunotherapeutic solutionsto fight and prevent human and animal diseases addressing unmet clinical needs in the main pharmaceutical markets. Our technology is based on patented and proprietary Ch-VLP platform (Chimeric Virus like Particles) derived from the Infectious Bursal Disease Virus (IBDV). Virus-like particles are empty and not infectious viral particles capable of incorporating antigens involved in different pathologies in order to potentiate and direct the humoral or cellular immune response. The potential of the platform to induce both kind of responses has been validated through immunogenic studies and in vivo proofs of concept.

Our business model is to develop innovative vaccines based on our proprietary technological platform up to phase I, where the product will be licensed to a larger biotech or pharmaceutical company

Our main product is Cervivax https://www.dropbox.com/s/p2s06bqm9toai3n/VLPbio.mov?dl=0, an immunotherapeutic vaccine focused on the treatment of cervical dysplasia and infections caused by HPV-16 (Human Papilloma Virus), which is responsible for most of the cases of cervical lesions detected all over the world. Although, there are prophylactic approaches to prevent viral infection, currently do not exist commercial therapeutic solutions to treat infections or lesions caused by the infection, other than surgery combined by chemotherapy. We position our product to cover this unmet need. We have an in vivo efficacy proof of concept of the product with excellent results, overpassing those of other therapies under development in terms of efficacy in absence of any adyuvant (1).

The overall aim of the project that we are submitting is bring Cervivax from the current status up to clinical-phase I, where we are aiming to license it to a large biotech or pharma company. Currently we have two preliminary agreements with 2 leading pharma companies, which are in due diligence phase

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CERVIVAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CERVIVAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

sFilm-FS (2018)

Fibrin sealant for anastomotic leaks and haemostasis

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More